Document resource
Background and Importance CatSalut Pharmacotherapeutic Harmonisation Program (PHP) guarantees equity in access to hospital medications, taking into account the optimisation of resources in public healthcare system.PHP considers a responder patient to migraine prophylaxis treatment when, 3 months after initiation, he achieves 50% reduction in monthly migraine days (MMDs) or 30% reduction with a decrease of HIT6 scale.Aim and Objectives Analyse response to migraine prophylaxis treatments, according to PHP criteria.Material and Methods Retrospective cross-sectional observational study analysing response to migraine prophylaxis treatments initiated since 2019.Patient demographic variables, episodic or chronic migraine (EM/CM), treatments, MMDs and HIT6 score in baseline and month-3 were recorded.Results 73 treatments were initiated, of which 67 were included in study.16(24%) EM and 51(76%) CM treatments were recorded.Regarding EM, response data were obtained in 81% (N=13) of treatments: 2 atogepant, 1 erenumab, and 10 fremanezumab. A mean of 11 MMDs and 52 HIT6 score were recorded at beginning of treatment. 3 months after, a mean of 3 MMDs and 24 HIT6 score were recorded. 62% (N=8) of treatments were responders: 1/2 atogepant, 1/1 erenumab, and 6/10 fremanezumab. 38% (N=5) were non-responders: 4/10 fremanezumab and 1/2 atogepant.Regarding CM, response data were obtained in 84% (N=43) of treatments: 9 atogepant, 7 erenumab, 16 fremanezumab, and 11 galcanezumab. A mean of 19 MMDs and 61 HIT6 score were recorded at beginning of treatment. 3 months after, a mean of 10 MMDs and 47 HIT6 score were recorded. 65% (N=28) of treatments were responders: 4/9 atogepant, 6/7 erenumab, 13/16 fremanezumab, and 5/11 galcanezumab. 35% (N = 15) were non-responders: 5/9 atogepant, 1/7 erenumab, 3/16 fremanezumab and 6/11 galcanezumab.64% of the 56 treatments initiated (in wich a response was recorded) atachieved objectives set by PHP to be responder.Conclusion and Relevance 64% of migraine prophylaxis treatments were responders. Of the first-line drugs, fremanezumab showed a 73% response rate; followed by atogepant with 45%. Galcanezumab, most frequently used in second-line treatment, showed a 45% response rate, and erenumab, the least used due to its safety profile, showed an 87% response rate.Actually, therapeutic options have expanded, and a deeper understanding of them is needed to aid in decision-making process, ensure rational drug use and equity in access of hospital medicines.Conflict of Interest No conflict of interest